Medicago says it has received promising early test results for its plant-derived vaccine for the novel coronavirus.
The Quebec City-based company says interim results of a Phase 1 clinical trial found that 100 per cent of subjects developed a promising antibody response after two doses of its COVID-19 vaccine candidate.
Medicago says the side effects were generally mild to moderate and short in duration.
Get weekly health news
The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy people.
Based on the Phase 1 data, Medicago plans to proceed with a Phase 2/3 clinical trial for its COVID-19 vaccine candidate, subject to regulatory approval.
The federal government has signed a $173-million contract with Medicago to secure the rights to buy 76 million doses of its vaccine, should it meet health and safety standards.
- Hundreds of public sector workers warned their jobs could be cut: union
- Health Canada recalls glucose monitors that may give ‘incorrect’ readings
- ‘Patients get relief’: Researchers recommending nerve blockers to treat migraines
- Colleen Jones remembered: Funeral, celebration of life honours famed curler, broadcaster
Comments